News & Sentiment
CINF Q2 Earnings Miss Estimates, Revenues Rise Y/Y on Premium Growth
Cincinnati Financial's Q2 results reflected premium growth and higher investment income, but elevated catastrophe losses hurt underwriting and earnings.
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
383 articles
📰
Grifols (GRFS) Q2 2026 Earnings Call Transcript
CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.
📰
Centene (CNC) Q2 2026 Earnings Call Transcript
Sarah London discusses margin expansion and dual-eligible Medicare focus.
📰
Tilray Brands, Inc. (TLRY) Reports Q4 Loss, Beats Revenue Estimates
Tilray Brands (TLRY) delivered earnings and revenue surprises of -2,050.00% and +9.14%, respectively, for the quarter ended May 2026. Do the numbers...
📰
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
In the latest trading session, DaVita HealthCare (DVA) closed at $239.46, marking a +1.33% move from the previous day.
📰
Chemed (CHE) Tops Q2 Earnings and Revenue Estimates
Chemed (CHE) delivered earnings and revenue surprises of +9.19% and +1.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues...
📰
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Gilead Sciences (GILD) reached $134.32 at the closing of the latest trading day, reflecting a +2.91% change compared to its last close.
📰
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.32, indicating a -3.04% shift from the previous trading day.
📰
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.
📰
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know
In the most recent trading session, Novavax (NVAX) closed at $7.37, indicating a -1.6% shift from the previous trading day.
📰
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.
These 3 Companies Reported Record Results and Raised Guidance
Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking...
📰
NANO-X DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Nano-X Imaging Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NNOX
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X...
📰
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?
Martine Rothblatt exercised options at $135.42 and sold at $530.42 under a pre-established Rule 10b5-1 plan, reducing her stake by just 1% while...
Martin Madaus Elected to Haemonetics Board of Directors
BOSTON, July 28, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) a global medical technology company focused on delivering innovative...
📰
[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report - Stock Titan
[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report Stock Titan
Historic Vermont General Store Featured in Baby Boom Hits the Market After Award-Winning Revival
PERU, Vt., July 28, 2026 /PRNewswire/ -- One of Vermont's most recognizable country stores—and the beloved filming location from the 1987 classic...
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
📰
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits - Fox Business
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits Fox BusinessJohnson & Johnson agrees to pay $5.5 billion in talc powder...
📰
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
The company isn't resting on its laurels.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
📰
3 Dividend Stocks That Are Crushing the Market in 2026
These stocks are all up more than 28% this year.
📰
AMN or RTO: Which Is the Better Value Stock Right Now?
AMN vs. RTO: Which Stock Is the Better Value Option?
📰
5 Undervalued Price-to-Book Stocks Worth Adding to Your Portfolio
Harmony Biosciences, Invesco, GM, HPE and Quanex made the screen of low price-to-book stocks that also met multiple value metrics.
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026...
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026...
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026...
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1...
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1...
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.